NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $3.54 -0.07 (-1.94%) Closing price 04:00 PM EasternExtended Trading$3.54 0.00 (-0.14%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Niagen Bioscience Stock (NASDAQ:NAGE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$3.50▼$3.6250-Day Range$3.61▼$5.0252-Week Range$3.50▼$14.69Volume812,331 shsAverage Volume1.09 million shsMarket Capitalization$281.94 millionP/E Ratio16.86Dividend YieldN/APrice Target$14.67Consensus RatingModerate Buy Company Overview Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. Read More Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 86% of companies evaluated by MarketBeat, and ranked 66th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingNiagen Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialNiagen Bioscience has a consensus price target of $14.67, representing about 314.3% upside from its current price of $3.54.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 3 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth36.36% Earnings GrowthEarnings for Niagen Bioscience are expected to grow by 36.36% in the coming year, from $0.22 to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 16.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.34.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 16.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.06.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 3.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted6.96% of the float of Niagen Bioscience has been sold short.Short Interest Ratio / Days to CoverNiagen Bioscience has a short interest ratio ("days to cover") of 3.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Niagen Bioscience has recently decreased by 7.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment0.76 News SentimentNiagen Bioscience has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Niagen Bioscience this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders10.00% of the stock of Niagen Bioscience is held by insiders.Percentage Held by Institutions15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAGE Stock News HeadlinesNiagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ ScienceJune 2 at 8:32 AM | businesswire.comAnalysts Are Bullish on Top Healthcare Stocks: Niagen Bioscience (NAGE), Guardant Health (GH)May 29, 2026 | theglobeandmail.comJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before major runs - says the window to get in early is closing fast. Brown is showing investors how to claim a stake in Elon Musk's company before it hits the public markets. Once the IPO happens, this pre-public opportunity disappears.June 2 at 1:00 AM | Brownstone Research (Ad)National Advertising Review Board Recommends Niagen Modify or Discontinue Certain Tru Niagen NAD+ Dietary Supplement ClaimsMay 21, 2026 | markets.businessinsider.comNiagen Bioscience Earnings Call Highlights Growth PushMay 20, 2026 | tipranks.comHow The Niagen Bioscience (NAGE) Story Is Shifting As Price Targets Edge LowerMay 15, 2026 | finance.yahoo.comAssessing Niagen Bioscience (NAGE) Valuation After Earnings Strength And New NAD Plus Delivery InitiativesMay 11, 2026 | finance.yahoo.comNiagen Bioscience Reports Q1 Results, Updates 2026 OutlookMay 10, 2026 | theglobeandmail.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $6.36 at the start of the year. Since then, NAGE stock has decreased by 44.3% and is now trading at $3.54. How were Niagen Bioscience's earnings last quarter? Niagen Bioscience, Inc. (NASDAQ:NAGE) issued its quarterly earnings results on Wednesday, May, 6th. The company reported $0.07 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. The company had revenue of $31.47 million for the quarter. Niagen Bioscience had a net margin of 14.29% and a trailing twelve-month return on equity of 22.68%. Who are Niagen Bioscience's major shareholders? Niagen Bioscience's top institutional shareholders include SteelPeak Wealth LLC (4.24%), Arrowstreet Capital Limited Partnership (2.99%), Renaissance Technologies LLC (1.67%) and Dimensional Fund Advisors LP (1.34%). Insiders that own company stock include Frank L Jaksch Jr, Brianna Gerber, Ozan Pamir and Kristin Patrick. View institutional ownership trends. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2026Today6/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NAGE's financial health is in the Red zone, according to TradeSmith. NAGE has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 WebN/A Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Price Target for Niagen Bioscience$14.67 High Price Target$23.00 Low Price Target$10.00 Potential Upside/Downside+314.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio16.86 Forward P/E Ratio16.09 P/E GrowthN/ANet Income$17.38 million Net Margins14.29% Pretax Margin15.10% Return on Equity22.68% Return on Assets16.23% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio3.55 Sales & Book Value Annual Sales$130.42 million Price / Sales2.16 Cash Flow$0.19 per share Price / Cash Flow19.03 Book Value$0.96 per share Price / Book3.69Miscellaneous Outstanding Shares79,644,000Free Float71,680,000Market Cap$281.94 million OptionableN/A Beta2.17 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NAGE) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredI stumbled into this at 3 PMEvery trading day, $55 billion floods the market in the final hour between 3 and 4 PM Eastern. One trader noti...Trade To Close | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
